Please login to the form below

Not currently logged in
Email:
Password:

Reshma Kewalramani joins Vertex Pharmaceuticals as CMO

She will succeed Jeffrey Chodakewitz

Vertex Pharmaceuticals, a biotech known for its clinical development programmes in cystic fibrosis, has appointed a new chief medical officer in the form of Reshma Kewalramani.

She succeeds Jeffrey Chodakewitz, who will remain at the company as a senior advisor through early 2019.

Jeffrey Leiden, chairman, president and chief executive officer of Vertex, said: “Reshma’s depth of medical knowledge, paired with her experience and proven track record as a clinical leader at Vertex, makes her an ideal successor to Jeff.

“I look forward to working with her to continue to advance our clinical development pipeline in cystic fibrosis and other serious diseases.”

Prior to joining the biotech, Kewalramani served as vice president, head of the US medical organisation at Amgen, where she spent 12 years in various capacities.

She said: “It’s a privilege to work at a company with such a relentless focus on science and deep commitment to improving the lives of patients and their families.

“I am excited to assume the role of CMO and continue our important work to help more people with cystic fibrosis and other serious diseases alongside the talented team at Vertex.”

6th March 2018

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics